医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Rio Tinto and WA Government launch industry first vaccination blitz

2021年08月19日 PM01:30
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Rio Tinto is partnering with the Western Australian Government to launch a COVID-19 vaccination blitz targeting communities in the Pilbara and the fly-in fly-out workforce.

Following positive discussions between Rio Tinto and the WA Department of Health, vaccination hubs will be established in the Pilbara and at a trial clinic at Perth Airport to make vaccinations more accessible.

Starting with Tom Price, planning is underway for hubs at several locations in the Pilbara, with vaccines available to members of the local community, Indigenous communities, Rio Tinto employees, contractors and their families.

Rio Tinto is working with the Department of Health and the Shire of Ashburton and is close to finalising a location for the proposed Tom Price hub. The facility could potentially offer vaccines to the entire adult population of Tom Price and surrounding communities.

Rio Tinto’s COVID-19 screening facilities at Perth Airport (T2 and T3) will also be modified to include ‘pop-up’ vaccination hubs to target workers returning to Perth. The hubs will initially be available to Rio Tinto’s FIFO workforce, who regularly travel to and from the Pilbara, with the option to expand the vaccination service to the wider FIFO community.

The initial vaccination blitz is expected to commence in September, subject to availability of vaccines. Rio Tinto will work with the WA Government to finalise details in the coming weeks.

Rio Tinto Iron Ore chief executive Simon Trott said the company stood ready to support the WA Government’s vaccination rollout in any way it can.

“We are pleased to work in partnership with the WA Government on this industry-first vaccination blitz, which we expect will help boost vaccination rates in the Pilbara.

“This is an important development in our state’s effort to combat COVID-19. We know vaccinations are our best way out of this pandemic and we are very happy to convert our existing screening facilities, which have helped keep COVID-19 out of our operations and vulnerable communities for almost 18 months, to include vaccination hubs.

“Given Rio Tinto’s large operational footprint in the Pilbara, we are well positioned to support the WA Government’s vaccination rollout in the region, ensuring the vaccine is more accessible to remote and vulnerable communities.

“Plans are being developed to establish additional hubs in places like Paraburdoo, Pannawonica and Dampier, following the Tom Price vaccine blitz.

“While the initial vaccine blitz at Perth Airport will target Rio Tinto’s FIFO workforce, we will work with the WA Government to make our facilities available to others in the industry and community.

“Throughout the COVID-19 pandemic, the resources sector has worked hard to continue to operate in a COVID-safe way. The next step in is to play our part in making the vaccine accessible to as many Western Australians as possible.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005863/en/

CONTACT

Please direct all enquiries to

Media.enquiries@riotinto.com

Media Relations, Australia

Jonathan Rose

M +61 447 028 913

Matt Chambers

M +61 433 525 739

Jesse Riseborough

M +61 436 653 412

Jamie Macdonald

M +61 467 725 517

Rio Tinto plc

6 St James’s Square

London SW1Y 4AD

United Kingdom

T +44 20 7781 2000

Registered in England

No. 719885

Rio Tinto Limited

Level 7, 360 Collins Street

Melbourne 3000

Australia

T +61 3 9283 3333

Registered in Australia

ABN 96 004 458 404

riotinto.com

Category: General

同じカテゴリーの記事 

  • Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
  • Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024
  • Exergen起诉Baxter International,以捍卫其公布口腔体温计准确性数据的权利
  • Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
  • HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting